Jul 24, 2024 | News
Calgary, Alberta – July 24, 2024 – Marvel Biosciences Corp. (TSXV: MRVL OTC: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), today is pleased to announce the extension of its collaboration with Drs. Julie Le...
Jul 19, 2024 | News
Calgary, Alberta, Canada, July 19, 2024 – Marvel Biosciences Corp. (TSX-V: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), is pleased to report that, further to its press releases of May 16, 2024 and...
Jul 9, 2024 | News
Calgary, Alberta, Canada July 9, 2024 – Marvel Biosciences Corp. (TSXV: MRVL OTC: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), is pleased to highlight the recently published paper “Neuronal A2A receptor...
May 16, 2024 | News
Calgary, Alberta, Canada, May 16, 2024 – Marvel Biosciences Corp. (TSX-V: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), is pleased to announce a proposed non-brokered private placement of up to...
Mar 25, 2024 | News
Calgary, Alberta – March 25, 2024 – Marvel Biosciences Corp. (TSXV: MRVL OTC: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), today reported promising interim results from its acute study on MB-204 conducted...
Mar 12, 2024 | News
Calgary, Alberta – March 12, 2024 – Marvel Biosciences Corp. (TSXV: MRVL OTC: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), today reported promising interim results from its study on MB-204, a new...
